11 July 2018 - - Singapore-based international association of pharmaceutical companies Mundipharma LAM has entered into an agreement with Swiss Neovii pharmaceuticals AG giving Mundipharma the rights to develop and distribute Neovii's polyclonal antibody immunosuppressant Grafalon, in China and Japan, the company said.
Under its license, Mundipharma intends to strengthen the distribution and support of Grafalon, in these markets. Grafalon is currently available in over 50 countries worldwide.
Grafalon is a rabbit anti-human T-lymphocyte immunoglobulin used, where approved, as part of immunosuppressive regimens for the prevention of graft-vs-host disease in stem cell transplant, prevention and treatment of rejection in solid organ transplantation, or as immunosuppressive in the treatment of aplastic anemia.
Mundipharma is committed to providing affordable treatment and is focused on specialist therapy areas including analgesia, oncology, ophthalmology, respiratory, specialty care, and consumer healthcare. The company has an established business presence in six continents, innovative research and development, and eight manufacturing facilities around the world with headquarters in Cambridge and Singapore.